BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function

Summary

The study aims to investigate whether oral betablocker (BB) therapy is superior to no such treatment following an acute myocardial infarction (AMI).

Conditions

• Acute Myocardial Infarction
• Non-ST Elevation Myocardial Infarction
• ST Elevation Myocardial Infarction

Interventions

OTHER

Non-betablocker

No betablocker will be administered. Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Any other treatment or management is to be given as per usual care.

DRUG

Betablocker

A betablocker will be administered. To reflect contemporary management, for which this study is designed to test, there will not be a defined minimum dosage. The type and dose of BB will be left at the discretion of the PI. Generic drug and accepted dosages will be: * Metoprolol succinate up to a total dose of 200mg daily * Bisoprolol up to a total dose of 10mg daily * Carvedilol up to a total dose of 50mg daily The treating physician will be encouraged to aim for an equipotent dose of 100 mg metoprolol succinate or higher. Any other treatment or management is to be given as per usual care.

Sponsors & Collaborators

• Vestre Viken Hospital Trust

  collaborator OTHER

• The Hospital of Vestfold

  collaborator OTHER

• University of Oslo

  collaborator OTHER

• Helse Stavanger HF

  collaborator OTHER_GOV

• Haukeland University Hospital

  collaborator OTHER

• St. Olavs Hospital

  collaborator OTHER

• University Hospital of North Norway

  collaborator OTHER

• Sorlandet Hospital HF

  collaborator OTHER_GOV

• Norwegian University of Science and Technology

  collaborator OTHER

• Sykehuset Innlandet HF

  collaborator OTHER

• Nordlandssykehuset HF

  collaborator OTHER

• Lovisenberg Diakonale Hospital

  collaborator OTHER

• Diakonhjemmet Hospital

  collaborator OTHER

• Ostfold Hospital Trust

  collaborator OTHER

• Oslo University Hospital

  lead OTHER

Principal Investigators

• Dan Atar, MD Prof · Oslo University Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-10-01

Primary Completion

2025-04-04

Completion

2035-12-10

Countries

• Norway

Study Locations